このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

中程度から重度のプラーク乾癬の参加者におけるプラセボおよびウステキヌマブと比較して、JNJ-77242113の有効性と安全性を評価する研究 (ICONIC-ASCEND)

2026年11月2日 更新者:Janssen Research & Development, LLC

中程度から重度のプラーク乾癬患者の治療に対するJNJ-77242113の有効性と安全性を評価するために、第3相マルチセンター、ランダム化、二重盲検、プラセボ対照、ウステキヌマブ活性コンパレータ対照研究

The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.

調査の概要

研究の種類

介入

入学 (実際)

752

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Alabama
      • Birmingham、Alabama、アメリカ、35244
        • Cahaba Research Inc
    • California
      • Encinitas、California、アメリカ、92024
        • California Dermatology & Clinical Research Institute
      • Encino、California、アメリカ、91436
        • T Joseph Raoof Md Inc
      • Fountain Valley、California、アメリカ、92708
        • First OC Dermatology
      • Oceanside、California、アメリカ、92056
        • Dermatologist Medical Group of North County, Inc.
      • Rocklin、California、アメリカ、95765
        • NorCal Clinical Research
      • Sacramento、California、アメリカ、95815
        • Integrative Skin Science and Research
      • San Diego、California、アメリカ、92103
        • MedDerm Associates
      • Santa Ana、California、アメリカ、92701
        • Southern California Dermatology
      • Sylmar、California、アメリカ、91342
        • Olive View-UCLA Education & Research Institute
    • Connecticut
      • Farmington、Connecticut、アメリカ、06030
        • University of Conn Health Center
    • Florida
      • Miami、Florida、アメリカ、33155
        • Bioclinical Research Alliance Inc.
      • Miami、Florida、アメリカ、33126
        • Driven Research LLC
      • Ocala、Florida、アメリカ、34470
        • Renstar Medical Research
      • Tampa、Florida、アメリカ、33613
        • Forcare Clinical Research Inc
    • Georgia
      • Alpharetta、Georgia、アメリカ、30022
        • Hamilton Research LLC
    • Illinois
      • Skokie、Illinois、アメリカ、60076
        • Northshore Medical Group
    • Indiana
      • Plainfield、Indiana、アメリカ、46168
        • Indiana Clinical Trial Center
    • Iowa
      • Iowa City、Iowa、アメリカ、52242
        • University of Iowa
    • Kentucky
      • Bowling Green、Kentucky、アメリカ、42104
        • Equity Medical
    • Massachusetts
      • Boston、Massachusetts、アメリカ、02111
        • Tufts Medical Center
      • Brighton、Massachusetts、アメリカ、02135
        • Metro Boston Clinical Partners
    • Michigan
      • Caledonia、Michigan、アメリカ、49316
        • The Derm Institute of West Michigan
      • Detroit、Michigan、アメリカ、48202
        • Henry Ford Hospital
      • Fort Gratiot、Michigan、アメリカ、48059
        • Hamzavi Dermatology
      • Troy、Michigan、アメリカ、48084
        • Somerset Skin Centre
    • Minnesota
      • New Brighton、Minnesota、アメリカ、55112
        • Minnesota Clinical Study Center
    • Missouri
      • Kirksville、Missouri、アメリカ、63501
        • Cleaver Dermatology
      • Saint Joseph、Missouri、アメリカ、64506
        • MediSearch Clinical Trials
    • New York
      • New York、New York、アメリカ、10075
        • Sadick Research Group
      • New York、New York、アメリカ、10028
        • Mount Sinai Doctors Dermatology
    • North Carolina
      • Wilmington、North Carolina、アメリカ、28405
        • Wilmington Dermatology Center
    • Ohio
      • Boardman、Ohio、アメリカ、44512
        • Optima Research
      • Mayfield Heights、Ohio、アメリカ、44124
        • Apex Dermatology Mayfield Heights
    • Oregon
      • Portland、Oregon、アメリカ、97210
        • Oregon Dermatology and Research Center
      • Portland、Oregon、アメリカ、97201
        • Oregon Medical Research Center
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19114
        • Clinical Research Philadelphia
      • Pittsburgh、Pennsylvania、アメリカ、15213
        • UPMC Department of Dermatology
    • South Dakota
      • Rapid City、South Dakota、アメリカ、57702
        • Health Concepts
    • Tennessee
      • Nashville、Tennessee、アメリカ、37211
        • Advanced Research Experts PLLC
    • Texas
      • Arlington、Texas、アメリカ、76011
        • Arlington Research Center, Inc.
      • Dallas、Texas、アメリカ、75231
        • Modern Research Associates PLLC
      • Houston、Texas、アメリカ、77004
        • Center for Clinical Studies 1
      • San Antonio、Texas、アメリカ、78218
        • Texas Dermatology and Laser Specialists
      • San Antonio、Texas、アメリカ、78213
        • Progressive Clinical Research
      • Webster、Texas、アメリカ、77598
        • Center for Clinical Studies
    • Utah
      • West Valley City、Utah、アメリカ、84120
        • Kalo Clinical Research
    • Washington
      • Mill Creek、Washington、アメリカ、98012
        • Frontier Derm Partners CRO, LLC
      • Barrio Gral Paz Cba Capital、アルゼンチン、X5000
        • Consultora Integral de Salud SRL
      • Buenos Aires、アルゼンチン、B1643CRO
        • Instituto Medico De Alta Complejidad (IMAC)
      • Buenos Aires、アルゼンチン、C1417EYG
        • Mindout Research
      • Buenos Aires、アルゼンチン、C1425
        • Instituto de Neumonologia y Dermatologia
      • CABA、アルゼンチン、C1061AAS
        • CIPREC
      • CABA、アルゼンチン、C1199ABB
        • Hospital Italiano de Buenos Aires
      • CABA、アルゼンチン、C1055AAO
        • Buenos Aires Skin
      • CABA、アルゼンチン、C1056ABH
        • Investigaciones Medicas IMOBA SRL
      • CABA、アルゼンチン、C1128
        • Mautalen Salud e Investigacion
      • Caba、アルゼンチン、C1122AAF
        • Halitus Instituto Medico S.A. - Dermatologia y Estetica
      • Rosario、アルゼンチン、S2000DBS
        • Instituto De Especialidades De La Salud SRL
      • San Fernando、アルゼンチン、B1646
        • MR Medicina Reumatologica
      • San Miguel de Tucumán、アルゼンチン、T4000
        • Instituto de Investigaciones Medicas Tucuman
      • Dudley、イギリス、DY1 2HQ
        • Dudley Group NHS Foundation Trust
      • Harrow、イギリス、HA1 3UJ
        • London North West University Healthcare NHS Trust
      • Kings Lynn、イギリス、PE30 4ET
        • The Queen Elizabeth Hospital NHS Foundation Trust
      • London、イギリス、SE1 9RT
        • Guys and St Thomas NHS Foundation Trust
      • Reading、イギリス、RG1 5AN
        • Royal Berkshire Hospital
      • Salford、イギリス、M6 8HD
        • Salford Royal Hospital
      • Southampton、イギリス、So166yd
        • University Hospital Southampton
      • Wakefield、イギリス、WF1 4DG
        • Mid Yorkshire Hospital NHS Trust- Pinderfields Hospital
      • Clayton、オーストラリア、3168
        • Monash Medical Centre
      • Coorparoo、オーストラリア、4151
        • Cornerstone Dermatology
      • Greenslopes、オーストラリア、4120
        • Veracity Clinical Research
      • Kogarah、オーストラリア、2217
        • Premier Specialists
      • Melbourne、オーストラリア、3004
        • The Alfred Hospital
      • Melbourne、オーストラリア、3050
        • Royal Melbourne Hospital
      • Mitcham、オーストラリア、3132
        • ISHI dermatology
      • Westmead、オーストラリア、2145
        • Westmead Hospital
      • Feldkirch、オーストリア、6800
        • LKH Feldkirch
      • Linz、オーストリア、4020
        • Kepler Universitatsklinikum GmbH
      • Sankt Pölten、オーストリア、3100
        • Universtitatsklinikum St Poelten
      • Vienna、オーストリア、1090
        • Allgemeines Krankenhaus der Stadt Wien
    • Newfoundland and Labrador
      • St. John's、Newfoundland and Labrador、カナダ、A1E 1V4
        • Skincare Studio Inc Dermatology Clinical Trials
    • Ontario
      • Ajax、Ontario、カナダ、L1S7K8
        • CCA Medical Research Corporation
      • Barrie、Ontario、カナダ、L4M 7G1
        • SimcoDerm Medical and Surgical Dermatology Centre
      • Hamilton、Ontario、カナダ、L8N 1Y2
        • Dermatrials Research
      • London、Ontario、カナダ、N6A 5R9
        • Lovegrove Dermatology
      • Markham、Ontario、カナダ、L3P 1X3
        • Lynderm Research Inc.
      • Waterloo、Ontario、カナダ、N2J 1C4
        • Alliance Clinical Trials
    • Quebec
      • Montreal、Quebec、カナダ、H2X 2V1
        • Innovaderm Research Inc.
      • Québec、Quebec、カナダ、G1W 4R4
        • The Centre de recherche Saint-Louis
      • Alicante、スペイン、03010
        • Hosp. Gral. Univ. Dr. Balmis
      • Barakaldo、スペイン、48902
        • Hosp. Univ. de Cruces
      • Barcelona、スペイン、08036
        • Hosp. Clinic de Barcelona
      • Granada、スペイン、18016
        • Hosp. Univ. San Cecilio
      • Madrid、スペイン、28041
        • Hosp. Univ. 12 de Octubre
      • Madrid、スペイン、28006
        • Hosp. Univ. de La Princesa
      • Madrid、スペイン、28002
        • Grupo Dermatologico Y Estetico Pedro Jaen
      • Manises、スペイン、46940
        • Hosp. de Manises
      • Santiago Compostela、スペイン、15706
        • Hosp. Clinico Univ. de Santiago
      • Seville、スペイン、41009
        • Hosp. Virgen Macarena
      • Seville、スペイン、41014
        • Hosp. Ntra. Sra. de Valme
      • Valencia、スペイン、46026
        • Hosp. Univ. I Politecni La Fe
      • Villajoyosa、スペイン、03570
        • Hosp. de La Marina Baixa
      • Zaragoza、スペイン、50009
        • Hosp. Clinico Univ. Lozano Blesa
      • Zaragoza、スペイン、50009
        • Hosp. Univ. Miguel Servet
      • Aalborg、デンマーク、9100
        • Aalborg Sygehus Syd
      • Aarhus、デンマーク、8200
        • Aarhus University Hospital
      • Hellerup、デンマーク、2900
        • Gentofte Hospital
      • København NV、デンマーク、2400
        • Bispebjerg Hospital
      • Odense、デンマーク、5000
        • Odense University Hospital
      • Roskilde、デンマーク、4000
        • Sjællands University hospital
      • Augsburg、ドイツ、86179
        • Klinikum Augsburg
      • Bad Bentheim、ドイツ、48455
        • Fachklinik Bad Bentheim
      • Berlin、ドイツ、10789
        • ISA - Interdisciplinary Study Association GmbH
      • Bonn、ドイツ、53127
        • Universitatsklinikum Bonn
      • Bramsche、ドイツ、49565
        • Studienzentrum an der Hase GbR
      • Darmstadt、ドイツ、64283
        • Rosenpark Research GmbH
      • Dresden、ドイツ、01307
        • Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden
      • Friedrichshafen、ドイツ、88045
        • Derma-Study-Center Friedrichshafen GmbH
      • Kiel、ドイツ、24105
        • Universitaetsklinikum Schleswig Holstein Campus Kiel
      • Langenau、ドイツ、89129
        • Studienzentrum Dr Schwarz Germany
      • Mahlow、ドイツ、15831
        • Dermatologie Mahlow
      • Mainz、ドイツ、55128
        • Gemeinschaftspraxis Dres. Quist
      • Münster、ドイツ、48149
        • Universitaetsklinikum Muenster
      • Witten、ドイツ、58453
        • Hautarztpraxis
      • Budapest、ハンガリー、1036
        • Obudai Egeszsegugyi Centrum Kft
      • Budapest、ハンガリー、1152
        • Uno Medical Trials Ltd.
      • Debrecen、ハンガリー、4032
        • Debreceni Egyetem Klinikai Kozpont
      • Debrecen、ハンガリー、4031
        • Derma-B Kft
      • Gyula、ハンガリー、5700
        • Synexus Magyarorszag Kft
      • Gyöngyös、ハンガリー、3200
        • Gyongyosi Bugat Pal Korhaz
      • Hódmezővásárhely、ハンガリー、6800
        • Porcika Klinika - Vasarhelyi Sarkanyfu Kft.
      • Kaposvár、ハンガリー、7400
        • Somogy Varmegyei Kaposi Mor Oktato Korhaz
      • Kecskemét、ハンガリー、6000
        • Bacs-kiskun Megyei Korhaz
      • Szolnok、ハンガリー、5000
        • Allergo-Derm Bakos Kft.
      • Veszprém、ハンガリー、8200
        • Medmare Egeszsegugyi Es Szolgaltato Bt.
      • Brussels、ベルギー、1090
        • UZ Brussel
      • Ghent、ベルギー、9000
        • Ghent University Hospital
      • Ghent、ベルギー、9000
        • AZ St. Lucas
      • Leuven、ベルギー、3000
        • Universitair Ziekenhuis Leuven
      • Liège、ベルギー、4000
        • Centre Hospitalier Universitaire de Liege Domaine Universitaire du Sart Tilman
      • Maldegem、ベルギー、9990
        • Dermatologie Maldegem
      • Guimarães、ポルトガル、4835 044
        • Uls Alto Ave - Hosp. Sra. Da Oliveira Guimaraes
      • Leiria、ポルトガル、2410 197
        • Unidade Local De Saude Da Regiao De Leiria Epe
      • Lisbon、ポルトガル、1169 050
        • Uls Sao Jose - Hosp. Sto Antonio Dos Capuchos
      • Lisbon、ポルトガル、1998 018
        • Hosp. Cuf Descobertas
      • Porto、ポルトガル、4099 001
        • Ulssa Hosp. Santo Antonio
      • Bialystok、ポーランド、15 375
        • Specderm Poznanska sp j
      • Bialystok、ポーランド、15-351
        • Osteo-Medic s.c A. Racewicz, J Supronik
      • Elblag、ポーランド、82 300
        • Centrum Kliniczno Badawcze J Brzezicki B Gornikiewicz Brzezicka Lekarze Spolka Partnerska
      • Katowice、ポーランド、40 568
        • Care Clinic Sp z o o
      • Krakow、ポーランド、30 002
        • Specjalistyczny gabinet dermatologiczny Aplikacyjno Badawczy Marek Brzewski Pawel Brzewski Spolka Cywilna
      • Lodz、ポーランド、90-265
        • Dermed Centrum Medyczne Sp z o o
      • Olsztyn、ポーランド、10-117
        • Etyka Osrodek Badan Klinicznych
      • Poznan、ポーランド、60 529
        • SOLUMED Centrum Medyczne
      • Skierniewice、ポーランド、96 100
        • Velocity Nova Sp z o o
      • Warsaw、ポーランド、02 661
        • Magdalena Opadczuk Carpe Diem Centrum Medycyny Estetycznej
      • Warsaw、ポーランド、02 953
        • Klinika Ambroziak Dermatologia
      • Wroclaw、ポーランド、52 416
        • Centrum Medyczne Oporow
      • Wroclaw、ポーランド、51 685
        • WroMedica I Bielicka A Strzalkowska s c

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

12年歳以上 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), prior to the first administration of study intervention
  • Total body surface area (BSA) greater than or equal to (>=)10 percent (%) at screening and baseline
  • Total psoriasis area and severity index (PASI) >=12 at screening and baseline
  • Total investigator global assessment (IGA) >=3 at screening and baseline
  • Candidate for phototherapy or systemic treatment for plaque psoriasis

Exclusion Criteria:

  • Nonplaque form of psoriasis (for example [e.g.], erythrodermic, guttate, or pustular)
  • Current drug-induced psoriasis (e.g., a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
  • Known allergies, hypersensitivity, or intolerance to JNJ-77242113, ustekinumab, or its excipients
  • Major surgical procedure within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study
  • Transplanted organ (with exception of a corneal transplant greater than [>] 12 weeks before the first administration of study intervention)

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的:Arm 1: JNJ 77242113

Participants will receive JNJ-77242113 once daily from Week 0 through Week 104. All participant will receive ustekinumab matching placebo at Week 0, 4 and 16 to maintain the blind.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

プラセボコンパレーター:Arm 2: Placebo

Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for ustekinumab at Week 0, 4 and 16 and JNJ-77242113 from Week 16 through Week 104.

JNJ-77242113 will be administered orally.

Matching placebo will be administered subcutaneously.

Matching placebo will be administered orally.

アクティブコンパレータ:Arm 3: Ustekinumab

Participants will receive Ustekinumab at Week 0, Week 4, and Week 16 followed by JNJ-77242113 once daily from Week 28 through Week 104. Participants will receive both Ustekinumab and placebo for JNJ-77242113 to maintain the blind through Week 28.

JNJ-77242113 will be administered orally.

Matching placebo will be administered orally.

Ustekinumab will be administered subcutaneously.

他の名前:
  • ステララ
  • CNTO1275

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
JNJ-77242113 and Placebo Group: Percentage of Participants with Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater than or Equal to (>=) 2 Grade Improvement from Baseline at Week 16
時間枠:Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
時間枠:Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16

二次結果の測定

結果測定
メジャーの説明
時間枠
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Week 16
時間枠:Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 75 response represents participants achieving at least a 75 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
時間枠:Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with IGA Score of 0 at Week 16
時間枠:Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 28
時間枠:Week 28

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 28
時間枠:Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 28
時間枠:Week 28

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 28
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 16
時間枠:Week 16

PSSD includes patient-reported outcome (PRO) questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 16
時間枠:Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 16
Number of Participants Reporting Adverse Events (AEs) and Serious Adverse Events (SAEs)
時間枠:Up to Week 108

An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. SAE is any untoward medical occurrence that results in: death, is life-threatening, requires in-patient hospitalization/prolongs existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of infectious agent via medicinal product & is medically important.

Up to Week 108
JNJ-77242113 and Placebo Group: Percentage of Participants with PSSD Sign Score of 0 at Week 16
時間枠:Week 16

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs for the assessment of treatment benefit. This PRO includes 11 items in total, with 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). A 0 to 10 numerical rating scale for severity is used to rank the psoriasis sign score. A higher score indicates more severe disease.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Dermatology Life Quality Index (DLQI) Score at Week 16
時間枠:Baseline up to Week 16

DLQI will be utilized in the adult population and is a dermatology specific health related quality of life (HRQoL) instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 16
JNJ-77242113 and Placebo Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 16
時間枠:Week 16

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10 item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 16
JNJ-77242113 and Placebo Group: Change from Baseline in Body Surface Area (BSA) Score at Week 16
時間枠:Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (that is., plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with >= 4 Point Improvement from Baseline in PSSD Itch Score at Week 28
時間枠:Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Sign Score at Week 28
時間枠:Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in PSSD Symptom Score at Week 28
時間枠:Baseline up to Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Sign Score of 0 at Week 28
時間枠:Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with PSSD Symptom Score of 0 at Week 28
時間枠:Week 28

PSSD includes PRO questionnaires designed to measure the severity of psoriasis symptoms and signs over the previous 7 days for the assessment of treatment benefit. This PRO includes 11 items in total, with 5 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and 6 items covering participant observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding). The PSSD itch score will range from 0 to 10. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in DLQI Score at Week 28
時間枠:Baseline up to Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Baseline up to Week 28
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with DLQI Score of 0 or 1 at Week 28
時間枠:Week 28

DLQI will be utilized in the adult population and is a dermatology specific HRQoL instrument designed to assess the impact of the disease on the HRQoL. It is a 10-item questionnaire that can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.

Week 28
JNJ-77242113 and Ustekinumab Group: Change from Baseline in BSA Score at Week 16
時間枠:Baseline up to Week 16

BSA is a commonly used measure of involvement of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed, (ie, plaque psoriasis). The handprint method for assessing BSA will be used, where the surface area of the participant's hand including the palm and all 5 digits is used as a guide to estimate 1% BSA.

Baseline up to Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants with IGA Score of 0 at Week 16
時間枠:Week 16

IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 90 Response at Week 16
時間枠:Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 90 response represents participants achieving at least a 90 percent improvement from baseline in the PASI score.

Week 16
JNJ-77242113 and Ustekinumab Group: Percentage of Participants Achieving PASI 100 Response at Week 16
時間枠:Week 16

PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In this system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 (none) to 4 (severe) and extent of involvement on a scale of 0 (indicates no involvement) to 6 (90% to 100% involvement). The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease. A PASI 100 response represents participants achieving at least a 100 percent improvement from baseline in the PASI score.

Week 16

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年4月15日

一次修了 (実際)

2025年11月17日

研究の完了 (推定)

2027年8月20日

試験登録日

最初に提出

2025年4月11日

QC基準を満たした最初の提出物

2025年4月11日

最初の投稿 (実際)

2025年4月18日

学習記録の更新

投稿された最後の更新 (実際)

2026年11月3日

QC基準を満たした最後の更新が送信されました

2026年11月2日

最終確認日

2026年11月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 77242113PSO3006
  • 77242113PSO3006 (その他の識別子:Janssen Research & Development, LLC)
  • 2024-515706-77-00 (レジストリ識別子:EUCT number)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

米国で製造され、米国から輸出された製品。

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する